Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylactic methylxanthines for extubation in preterm infants.

D J Henderson-Smart1, P G Davis

  • 1NSW Centre for Perinatal Health Services Research, Queen Elizabeth II Institute for Mothers and Infants, Building DO2, University of Sydney, Sydney, NSW, Australia. dhs@perinatal.usyd.edu.au

The Cochrane Database of Systematic Reviews
|January 22, 2003
PubMed
Summary

Methylxanthine treatment significantly reduces failed extubation in preterm infants within one week. This intervention improves weaning from respiratory support, with a number needed to treat of 3.7.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal Outcomes Following Antenatal Identification of Twin-To-Twin Transfusion Syndrome.

Acta paediatrica (Oslo, Norway : 1992)·2026
Same author

Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial).

Trials·2024
Same author

Introducing a novel respiratory function monitor for neonatal resuscitation training.

Resuscitation plus·2024
Same author

The α2,3-selective potentiator of GABA<sub>A</sub> receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.

Pharmacology, biochemistry, and behavior·2019
Same author

Nasal high-flow during neonatal and infant transport in Victoria, Australia.

Acta paediatrica (Oslo, Norway : 1992)·2018
Same author

Evaluation of an exercise programme for post-bariatric surgery patients: views of participants.

Obesity science & practice·2018

Area of Science:

  • Neonatal Medicine
  • Respiratory Physiology
  • Pharmacology

Background:

  • Preterm infants on intermittent positive pressure ventilation (IPPV) often face difficulties with weaning and extubation due to poor respiratory drive.
  • Hypercarbia and apnea are common in very preterm infants, complicating respiratory support withdrawal.
  • Methylxanthine therapy initiated before extubation may enhance respiratory stimulation and facilitate successful weaning.

Purpose of the Study:

  • To determine if methylxanthine treatment reduces the need for re-intubation and IPPV in preterm infants planned for extubation.
  • To assess if methylxanthine treatment is associated with clinically significant side effects in this vulnerable population.

Main Methods:

  • A systematic review of published randomized or quasi-random trials was conducted.

Related Experiment Videos

  • Searches included the Oxford Database of Perinatal Trials, Cochrane Central Register of Controlled Trials, and MEDLINE.
  • Methylxanthine treatment was compared against placebo or no treatment for improving extubation success in preterm infants.

    • Main Results:

    • Methylxanthine treatment reduced extubation failure within one week, with a summary relative risk of 0.47.
    • An absolute reduction of 27% in failed extubation was observed, indicating a number needed to treat of 3.7.
    • One study indicated benefit primarily in infants <1000g born and extubated within the first week; other subgroups showed no significant benefit.

    Conclusions:

    • Methylxanthines improve the likelihood of successful extubation in preterm infants within seven days.
    • The benefit appears most pronounced in extremely low birth weight infants extubated early; further research is needed on side effects and long-term outcomes.
    • Future trials should stratify by gestational age and evaluate caffeine's efficacy and safety, including neurodevelopmental follow-up.